New York bill would create a psychedelics research institute to study psilocybin treatment for substance use disorder and depression.

New York Bill Would Create State-Sponsored Psychedelics Research Institute

A new bill proposed in New York would create a psychedelic research institute to study the effect of psilocybin, LSD, MDMA, and ibogaine on conditions including addictive disorders, depression, PTSD, and end-of-life anxiety. The bill is sponsored by Assemblywoman Linda Rosenthal (D), who believes that “psychedelics provide a host of benefits without the same risk of overdose or dependency that other medications may provide”. The legislature suggests that “psilocybin is a breakthrough therapy for severe depression and nicotine addiction” and may also provide treatment for methamphetamine or opioid addiction.

PDF of article

PDF of bill